Exelixis (EXEL) Share-based Compensation Growth (5y) (2015 - 2026)
Exelixis (EXEL) Share-based Compensation Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 5.33% |
| Apr 3, 2026 | 44.46% |
| Jan 2, 2026 | 98.75% |
| Apr 4, 2025 | 10.00% |
| Sep 27, 2024 | 119.35% |
| Jun 28, 2024 | 15.88% |
| Mar 29, 2024 | 8.81% |
| Dec 29, 2023 | 10.19% |
| Sep 29, 2023 | -17.74% |
| Jun 30, 2023 | 67.08% |
| Mar 31, 2023 | 3.73% |
| Dec 30, 2022 | 34.32% |
| Sep 30, 2022 | 48.55% |
| Jul 1, 2022 | -66.79% |
| Apr 1, 2022 | 66.53% |
| Dec 31, 2021 | 35.50% |
| Jul 2, 2021 | -15.36% |
| Apr 2, 2021 | 23.24% |
| Apr 3, 2020 | 53.14% |
| Sep 27, 2019 | 5.54% |